# MAGNITUDE (NCT03748641)

> A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: niraparib plus abiraterone
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03748641
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Castration-Resistant Prostatic Cancer
- Interventions: Niraparib; Abiraterone Acetate; Prednisone; Placebo; New Formulation of Niraparib and Abiraterone Acetate (AA)
- Enrollment: 765
- Primary outcome: Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)

## Indexed commentary on MAGNITUDE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=magnitude-nct03748641